Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04145518 · ClinicalTrials.gov registry record · Phase 4

Mechanistic Characterization of Uterine Pain

A Phase 4 study, sponsored by Endeavor Health.

Completed
Registry status
Phase 4
Development phase
183
Enrollment target

NCT04145518: Completed Phase 4 study, sponsored by Endeavor Health.

NCT04145518 is a Phase 4 study that has completed, run by Endeavor Health. The registered enrollment target is 183 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04145518, a Phase 4 study, has completed, sponsored by Endeavor Health.

COMPLETED
Registry status
Phase 4
Development phase
183 participants
Enrollment target

Study Summary

There are limited treatment options for management of dysmenorrhea, and the physiological processes they affect are not completely understood. For example, NSAIDs are effective in reducing menstrual pain in some women by inhibition of prostaglandin synthesis, but whether those effects are mediated by affecting contractility, perfusion, or hypoxemia is unknown. Understanding how these drugs relieve menstrual pain (and why they fail) would be of substantial clinical significance. Given the foregoing, Two Specific Aims are proposed: Aim #1: Characterize menstrual pain phenotypes associated with impairments in myometrial activity, perfusion, and/or oxygenation. Continuous MRI scans of the uterus will be performed with simultaneous measurement of self-reported pain in healthy women and those experiencing menstrual pain. The investigators will include cohorts of women with imaging diagnosed leiomyoma and surgically-confirmed endometriosis to evaluate the contribution of structurally identifiable factors. Based on preliminary data, the investigators anticipate finding four phenotypes with menstrual pain related to: 1) myometrial activity, 2) inadequate perfusion and/or oxygenation, 3) a combination of phenotypes 1 \& 2, and 4) a non-uterine source. Aim #2: Evaluate the effects of naproxen on myometrial activity, perfusion, and/or oxygenation with respect to pain relief. In women with primary dysmenorrhea, the investigators will acquire pelvic MRI scans and evaluate self-reported menstrual cramping pain before and after administration of randomized naproxen or placebo. Naproxen could principally affect one or more potential sources of uterine pain such as myometrial activity, perfusion, and/or oxygenation. The investigators will corroborate preliminary data findings, which suggest menstrual phenotypes with myometrial activity will be more likely to respond. Conversely, Aim 2 will also elucidate the mechanisms responsible for inadequate pain relief from naproxen. Bioavai

Primary Outcome

The investigators will calculate the change in R2\*, ASL (arterial spin label), HASTE, and BOLD (Blood Oxygen Level Dependent) signal for each menstrual pain phenotype. Principal component analysis of derived MRI signal variables and subsequent scree plotting will be used to reduce the dataset to 4-6 representative parameters that meaningfully separate potential phenotypes via hierarchical cluster analysis (R cluster library). Cluster dissimilarity metrics will be used to establish the probable

Interventions

  • DRUG Naproxen Sodium

Trial Details

FieldValue
Enrollment Target 183 participants
Start Date 2019-10-25
Est. Completion 2025-07-23
Phase Phase 4
Endeavor Health

94 total trials

What the finished NCT04145518 record still lists

NCT04145518 is an interventional study that assigns participants to a tested intervention. The registered 183 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (65% lower).

The record links to 0 conditions, and to 1 intervention - of which Naproxen Sodium is the first listed.

NCT04145518 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04145518 about?

NCT04145518 is a clinical study titled "Mechanistic Characterization of Uterine Pain". There are limited treatment options for management of dysmenorrhea, and the physiological processes they affect are not completely understood. For example, NSAIDs are effective in reducing menstrual pain in some women by inhibition of prostaglandin synthesis, but whether those effects are mediated b...

What is the current status of trial NCT04145518?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 183 participants. The study started on 2019-10-25. Estimated completion is 2025-07-23.

What interventions are being tested in trial NCT04145518?

The interventions under investigation include: Naproxen Sodium (DRUG).

Who is sponsoring clinical trial NCT04145518?

This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04145518's enrollment target sits among peer trials

183 463rd of 2000 higher than 1,537 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03859297 · 183 participants · NA

    Mechanisms of Rumination Change in Adolescent Depression

  • NCT04270591 · 183 participants · Phase 1

    Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

  • NCT06764615 · 183 participants · Phase 2

    A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

  • NCT06872684 · 183 participants · NA

    Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04145518, the US trial registry maintained by the National Library of Medicine. NCT04145518 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.